A simple LC-MS/MS method for pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol at a low dose

Wanna Eiamart , Nantaporn Prompila, Yaowatree Jumroen, Nonlanee Sayankuldilok, Pajaree Chariyavilaskul, Supeecha Wittayalertpanya

Abstract


Background and purpose: The study was aimed at validating a simple, rapid, and low-cost LC-MS/MS method for carvedilol and 4/-hydroxyphenyl carvedilol assay in human plasma. The validated method was applied to investigate the pharmacokinetics after a low dose of 6.25 mg. carvedilol.

Experimental approach: In this study, the plasma was extracted by liquid-liquid extraction and evaporated the organic layer to dryness, then both analytes in the residue were reconstituted and detected by LC-MS/MS. The method was validated following the guideline on bioanalytical method validation. Thirty-one healthy volunteers participated in the pharmacokinetic study. After 10 h of fasting, each volunteer received one tablet of 6.25 mg carvedilol orally. Blood samples were collected at 16 prescheduled time points. The plasma samples were analyzed for pharmacokinetics.

Findings/Results: The method was linear over a range of 0.050-50.049 ng/mL for carvedilol and 0.050-10.017 ng/mL for 4/-hydroxyphenyl carvedilol. Crucial validated results reached the requirements of selectivity, accuracy, precision, and stability. Pharmacokinetics of carvedilol and 4/-hydroxyphenyl carvedilol were evaluated which showed Cmax at 21.26 ± 9.23 and 2.42 ± 2.07 ng/mL; AUC0-t 66.95 ± 29.45 and 5.93 ± 3.51 ng.h/mL; AUC0-inf 68.54 ± 30.11 and 6.78 ± 3.49 ng.h/mL; and T1/2 6.30 ± 1.95 and 6.31 ± 6.45 h, respectively.

Conclusion and implications: The validated method was able to detect and quantify both analytes in plasma samples and can be applied to the pharmacokinetic study of carvedilol and 4/-hydroxyphenyl carvedilol after receiving carvedilol at 6.25 mg orally.

Full Text:

PDF

References


McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993;45(2):232-258.

DOI: 10.2165/00003495-199345020-00006.

Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003;63(16):1697-1741.

DOI: 10.2165/00003495-200363160-00006.

Morgan T, Anderson A, Cripps J, Adam W. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypertens. 1990;4(6):709-715.

PMID: 2096213.

Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol. 1987;33(5):511-513.

DOI: 10.1007/BF00544245.

Sharma A, Jain CP. Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci. 2010;5(1):49-56.

PMID: 21589768.

McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs. 1988;36(Suppl 6):82-91.

DOI: 10.2165/00003495-198800366-00015.

Varin F, Cubeddu LX, Powell JR. Liquid chromatographic assay and disposition of carvedilol in health volunteers. J Pharm Sci. 1986;75(12):1195-1197.

DOI: 10.1002/jps.2600751218.

Neugebauer G, Akpan W, Mollendorff E, Neubert P, Reiff K. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovas Pharmacol. 1987;10 Suppl 11:S85-S88.

PMID: 2454375.

Neugebauer G, Neubert P. Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet. 1991;16(4):257-260.

DOI: 10.1007/BF03189969.

Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997;25(8):970-977.

PMID: 9280405.

Ruffolo RR Jr, Boyle DA, Venuti RP, Lukas MA. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens. 1993;7 Suppl 1:S2-S15.

PMID: 8487245.

Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999; 55(4):269-277.

DOI: 10.1007/s002280050628.

Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. Eur J Clin Pharmacol. 1992;43(1):85-88.

DOI: 10.1007/BF02280760.

Patel DP, Sharma P, Sanyal M, Singhal P, Shrivastav PS. UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers. Biomed Chromatogr. 2013;27(8):974-986.

DOI: 10.1002/bmc.2889.

Carmo Borges NC, Mendes GD, Oliveira Silva D, Rezende VM, Barrientos-Astigarraga RE, Nucci G. Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;822(1-2):253-262.

DOI: 10.1016/j.jchromb.2005.06.012.

Kim SH, Lee SH, Lee HJ. Rapid and sensitive carvedilol assay in human plasma using a high-performance liquid chromatography with mass/mass spectrometer detection employed for a bioequivalence study. Am J Anal Chem. 2010;1:135-143.

DOI: 10.4236/ajac.2010.13017.

U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical Method Validation Guidance for Industry. Biopharmaceutics; 2018. pp. 1-44.

Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation. European Medicines Agency, Science Medicines Health; 2011. pp. 1-23.

Nardotto GHB, Coelho EB, Marques MP, Lanchote VL. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1015-1016:173-180.

DOI: 10.1016/j.jchromb.2016.02.028.

Gangnus T, Burckhardt BB, Consortium CARS. Low-volume LC-MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: application to a paediatric clinical trial. Drug Test Anal. 2021;13(3):694-708.

DOI: 10.1002/dta.2949.

Huang Y, Zheng S, Pan Y, Li T, Xu ZS, Shao MM. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: application to their pharmacokinetic interaction study. J Pharm Biomed Anal. 2016;128:184-190.

DOI: 10.1016/j.jpba.2016.05.029.

Furlong MT, He B, Mylott W, Zhao S, Mariannino T, Shen J, et al. A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012;70:574-579.

DOI: 10.1016/j.jpba.2012.05.026.

Kim SM, Shin SB, Kim JH, Kwon IH, Kim YH, Lee SN. Bioequivalence of Cadilan tablet 12.5 mg to Dilatrend® tablet 12.5 mg (Carvedilol 12.5 mg). J Kor Pharm Sci. 2008;38(6):413-419.

DOI: 10.4333/KPS.2008.38.6.413.

Cho HY, Lee MS, Park SC, Lim DK, Moon JD, Lee YB. Bioequivalence of Carvelol tablet to Dilatrend tablet (Carvedilol 25 mg). J Kor Pharm Sci. 2001;3(4):289-295.

Jung E, Ryu S, Park Z, Lee JG, Yi JY, Seo DW. Influence of CYP2D6 polymorphism on the pharmacokinetic/pharmacodynamics characteristics of carvedilol in healthy Korean volunteers. J Korean Med Sci. 2018;33(27):e182,1-12.

DOI: 10.3346/jkms.2018.33.e182.

Honda M, Nozawa T, Igarashi N, Inoue H, Arakawa R, Ogura Y, et al. Effect of CYP2D6*10 on the Pharmacokinetics of R- and S-Carvedilol in Healthy Japanese Volunteers. Biol Pharm Bull. 2005;28(8):1476-1479.

DOI: 10.1248/bpb.28.1476.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.